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Nepal experienced approximately 42,000 cases of tuberculosis (TB) in 2018, equating to a national incidence rate of 151 per 100,000 individuals ([@B1]). Key challenges to TB control in Nepal include finding and treating so-called "missing cases" that are not registered through the National Tuberculosis Control Program (NTP) ([@B2]) and overcoming the prevalence of drug resistance. In Nepal in 2017, 2.2% of new cases and 15% of previously treated cases of TB were multidrug resistant (MDR) or rifampin resistant (RR), including 13 laboratory-confirmed cases of extensively drug-resistant (XDR) TB ([@B3]). Of particular concern are the relatively low treatment success rates of 68% and 61% observed in Nepal for MDR/RR-TB and XDR-TB, respectively ([@B1]).

We previously characterized XDR isolates of Mycobacterium tuberculosis using whole-genome sequencing ([@B4][@B5][@B6]). In this work, an XDR-TB isolate from Nepal, NP1701X, was grown in pure culture on Löwenstein-Jensen medium, and genomic DNA was prepared as previously described ([@B7], [@B8]). DNA libraries were generated using the Nextera XT library preparation kit (catalog number FC-131-1024; Illumina, USA) as described previously ([@B9]). Default parameters were used for all software unless otherwise specified. Sequencing of the isolate using an Illumina MiSeq instrument produced a total of 1,138,854 paired-end reads which mapped to the publicly available annotated genome of M. tuberculosis reference strain H37Rv (GenBank accession number [NC_000962.3](https://www.ncbi.nlm.nih.gov/nuccore/NC_000962.3)) ([@B10]) by Burrows-Wheeler alignment ([@B11]). This yielded an average read depth of 37.22-fold, covering 99.35% of the H37Rv genome. Variants relative to the H37Rv reference genome were called, and annotation was performed using Geneious Prime 2019.2.3. Variant calling was established using a minimum nucleotide variant frequency of 95% and a minimum sequence read depth of 20. A 4,326,340-bp draft genome assembly of 166 contigs (≥500 bp) was assembled *de novo* using the SPAdes assembler (v3.7) ([@B12]). Assembled contigs were ordered with respect to the M. tuberculosis H37Rv genome using ABACAS ([@B13]).

The NP1701X isolate belongs to the Beijing sublineage of East Asian lineage 2, as predicted by the PhyResSE and TB Profiler databases ([@B14], [@B15]). A total of 1,352 variant sites were identified in NP1701X relative to the H37Rv genome and consisted of 1,267 single-nucleotide variants (SNVs), 64 insertions/deletions, and 21 substitutions (of 2 or more adjacent nucleotides). A total of 791 of the variants were nonsynonymous, of which 725 were SNVs, 46 were insertions/deletions, and 20 were substitutions. The NP1701X genome displayed high-confidence single-nucleotide polymorphisms, as defined by Feuerriegel et al. ([@B14]), that are known to relate to antimicrobial drug resistance in M. tuberculosis based on clinical and experimental data. These include mutations in the *rpoB* gene (tCg/tTg, Ser450Leu), *fabG1-inhA* promoter (t-8c), *pncA* gene (gCc/gTc, Ala134Val), and *embB* gene (Atg/Gtg, Met306Val), which underlie M. tuberculosis resistance to the first-line drugs rifampin, isoniazid, pyrazinamide, and ethambutol, respectively ([@B16][@B17][@B18]). A further mutation was found in the *rpsL* gene (aAg/aGg, Lys43Arg) which is related to streptomycin resistance ([@B17]). Additional mutations detected in the *gyrA* gene (Tcg/Ccg, Ser91Pro) and *rrs* gene (A1401G) are associated with resistance to fluoroquinolones and second-line injectables (amikacin, kanamycin, and capreomycin), respectively ([@B18]). The identification of the latter mutations is in agreement with the extensively drug-resistant phenotype of the NP1701X isolate in culture. This study represents the first published genome sequence assembly of an XDR-TB isolate from Nepal and highlights the potential of using next-generation sequencing for drug resistance detection for medical laboratory diagnostics and surveillance.
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This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession number [WJSJ00000000](https://www.ncbi.nlm.nih.gov/nuccore/WJSJ00000000). The version described in this paper is the first version, WJSJ01000000. The associated BioProject, SRA, and BioSample accession numbers are [PRJNA587824](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA587824/), [SRP231411](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP231411), and [SAMN13219581](https://www.ncbi.nlm.nih.gov/biosample/SAMN13219581), respectively.
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